Abstract | BACKGROUND: OBJECTIVE: METHODS: We treated 18 patients; mean age, 40.5 years (standard deviation [SD], 9.9). The number of cluster headache attacks was recorded during a baseline period of 6 days, and during 6 days of treatment with eletriptan 40 mg twice daily. The primary outcome measure was the reduction in the number of attacks during the treatment period. RESULTS: In the 16 patients who completed the study (2 patients were lost to follow-up), the mean total number of attacks decreased from 10.9 (SD, 5.6) during baseline to 6.3 (SD, 3.7) during treatment with eletriptan (P=.01) The reduction in the number of attacks exceeded 50% in 6 patients. CONCLUSION: This small open-label study suggests that eletriptan 40 mg twice daily may be useful for the short-term prophylaxis of cluster headache.
|
Authors | Karin Zebenholzer, Christian Wöber, Marion Vigl, Peter Wessely |
Journal | Headache
(Headache)
Vol. 44
Issue 4
Pg. 361-4
(Apr 2004)
ISSN: 0017-8748 [Print] United States |
PMID | 15109360
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Indoles
- Pyrrolidines
- Serotonin Receptor Agonists
- Tryptamines
- eletriptan
|
Topics |
- Adult
- Cluster Headache
(prevention & control)
- Female
- Humans
- Indoles
(therapeutic use)
- Male
- Middle Aged
- Pilot Projects
- Pyrrolidines
(therapeutic use)
- Serotonin Receptor Agonists
(therapeutic use)
- Time Factors
- Treatment Outcome
- Tryptamines
|